Eli Lilly and Company (LLY)
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly (LLY) is set to report fourth-quarter earnings before the bell Thursday, with analysts expecting rising sales and profit in the first full quarter since the company's weight-loss drugs were declared no longer in shortage.
What Thursday's Earnings Mean for This Pharma Giant
Tomorrow, Eli Lilly (LLY), the world's largest drug company, reports earnings before the market opens. The options market is already predicting some major moves.
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly (LLY) is set to report fourth-quarter earnings before the bell Thursday, with analysts expecting rising sales and profit in the first full quarter since the company's weight-loss drugs were declared no longer in shortage.
Curious about Lilly (LLY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Lilly (LLY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
3 Magnificent Stocks to Buy and Hold Forever
Some people are fair-weather friends; others are lifelong. It's a similar story with stocks.
Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
Over the past six months, Eli Lilly (LLY -1.48%) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the undisputed leaders in the exciting market for weight loss drugs.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly Stock's Correction Brings Opportunity
I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation multiples are justified by robust growth prospects in FY2025 and FY2026 (likely beyond that as well). Risks include competition from Novo Nordisk and potential pricing pressures, which could impact margins and stock valuation.
Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Eli Lilly (LLY) closed at $804.99, marking a -0.39% move from the previous day.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
